These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 26370321)

  • 1. The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice.
    Polistena B; Calzavara-Pinton P; Altomare G; Berardesca E; Girolomoni G; Martini P; Peserico A; Puglisi Guerra A; Spandonaro F; Vena Gino A; Chimenti S; Ayala F
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2411-6. PubMed ID: 26370321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting.
    Küster D; Nast A; Gerdes S; Weberschock T; Wozel G; Gutknecht M; Schmitt J
    Arch Dermatol Res; 2016 May; 308(4):249-61. PubMed ID: 26961372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE.
    Klijn SL; van den Reek JMPA; van de Wetering G; van der Kolk A; de Jong EMGJ; Kievit W
    Br J Dermatol; 2018 May; 178(5):1181-1189. PubMed ID: 29247500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
    Duarte A; Mebrahtu T; Goncalves PS; Harden M; Murphy R; Palmer S; Woolacott N; Rodgers M; Rothery C
    Health Technol Assess; 2017 Nov; 21(64):1-244. PubMed ID: 29105621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept.
    Gholami A; Azizpoor J; Aflaki E; Rezaee M; Keshavarz K
    Biomed Res Int; 2021; 2021():4450162. PubMed ID: 34877355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
    Escudero-Vilaplana V; Ramírez-Herráiz E; Alañón-Plaza E; Trovato-López N; García-Vicuña R; Carreño-Pérez L; Morell-Baladrón A; Sanjurjo-Sáez M
    Int J Clin Pharm; 2015 Oct; 37(5):808-14. PubMed ID: 25910480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing therapeutic goals in maintenance treatment of psoriasis with biologics: adalimumab can be more cost-effective than infliximab or ustekinumab in real life.
    Puig L; Morales-Múnera CE
    Eur J Dermatol; 2013; 23(3):407-8. PubMed ID: 23782978
    [No Abstract]   [Full Text] [Related]  

  • 12. The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy.
    Spandonaro F; Ayala F; Berardesca E; Chimenti S; Girolomoni G; Martini P; Peserico A; Polistena B; Puglisi Guerra A; Vena GA; Altomare G; Calzavara Pinton P
    BioDrugs; 2014 Jun; 28(3):285-95. PubMed ID: 24567261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis.
    Feldman SR; Zhao Y; Navaratnam P; Friedman HS; Lu J; Tran MH
    J Manag Care Spec Pharm; 2015 Mar; 21(3):201-9. PubMed ID: 25726029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model for assessing the efficiency of biologic drugs in the treatment of moderate to severe psoriasis for one year in clinical practice in Spain.
    Puig L; López-Ferrer A; Vilarrasa E; García I; Fernández-del Olmo R
    Actas Dermosifiliogr; 2016; 107(1):34-43. PubMed ID: 26365029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
    Joensuu JT; Aaltonen KJ; Aronen P; Sokka T; Puolakka K; Tuompo R; Korpela M; Vasala M; Ilva K; Nordström D; Blom M
    Rheumatology (Oxford); 2016 Oct; 55(10):1803-11. PubMed ID: 27354689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic impact of etanercept in real-life: a prospective, non-interventional study of etanercept in the treatment of patients with moderate to severe plaque psoriasis in private dermatologist settings (ESTHER).
    Larsen CG; Andersen PH; Lorentzen H; Zachariae C; Huldt-Nystrøm T; Dotterud LK; Lindkvist RM; Qvitzau S
    Eur J Dermatol; 2013; 23(6):774-81. PubMed ID: 24334009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
    Sruamsiri R; Iwasaki K; Tang W; Mahlich J
    BMC Dermatol; 2018 Jul; 18(1):5. PubMed ID: 29996929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.